Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Adaptive Biotechnologies (ADPT) reported a Q4 loss of $0.23 per share, which was better than the Zacks Consensus Estimate of a $0.26 loss. This is an improvement from the $0.30 loss per share reported a year ago.
February 12, 2025 | 12:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptive Biotechnologies reported a Q4 loss of $0.23 per share, beating the Zacks Consensus Estimate of a $0.26 loss. This marks an improvement from the previous year's $0.30 loss per share.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to have a positive short-term impact on ADPT's stock price. The improvement from the previous year's loss also suggests positive momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100